Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Stefan Sleijfer"'
Autor:
Ibtissam Acem, Winan J. van Houdt, Dirk J. Grünhagen, Winette T.A. van der Graaf, Anja J. Rueten-Budde, Hans Gelderblom, Cornelis Verhoef, Michiel A.J. van de Sande, Will Aston, Han Bonenkamp, Ingrid M.E. Desar, Peter C. Ferguson, Marta Fiocco, Robert J. van Ginkel, Anthony M. Griffin, Rick L. Haas, Jos A. van der Hage, Andrew J. Hayes, Lee M. Jeys, Akira Kawai, Johnny Keller, Minna K. Laitinen, Katja Maretty-Kongstad, Koichi Ogura, Toshifumi Ozaki, Rob Pollock, Veroniek M. van Praag, Stefan Sleijfer, Myles J. Smith, Maria A. Smolle, Emelie Styring, Joanna Szkandera, Kazuhiro Tanaka, Per-Ulf Tunn, Madeleine Willegger, Reinard Windhager, Jay S. Wunder, Olga Zaikova
Publikováno v:
European Journal of Cancer, 165, pp. 71-80
European journal of cancer (Oxford, England : 1990), 165, 71-80. Elsevier Ltd.
European Journal of Cancer, 165, 71-80
European Journal of Cancer, 165, 71-80. ELSEVIER SCI LTD
European journal of cancer (Oxford, England : 1990), 165, 71-80. Elsevier Ltd.
European Journal of Cancer, 165, 71-80
European Journal of Cancer, 165, 71-80. ELSEVIER SCI LTD
Objective: The aim of the study is to assess the effect of perioperative chemo-therapy (CTX) in patients with grade II-III extremity soft tissue sarcoma (eSTS) on overall survival (OS) and evaluate whether the PERSARC prediction tool could identify p
Autor:
Khrystany T. Isebia, Bianca Mostert, Bodine P.S. Belderbos, Stefan A.J. Buck, Jean C.A. Helmijr, Jaco Kraan, Corine M. Beaufort, Mai N. Van, Esther Oomen - de Hoop, Anieta M. Sieuwerts, Wilfred F.J. van IJcken, Mirjam C.G.N. van den Hout - van Vroonhoven, Rutger W.W. Brouwer, Edwin Oole, Paul Hamberg, Brigitte C.M. Haberkorn, Helgi H. Helgason, Ronald de Wit, Stefan Sleijfer, Ron H.J. Mathijssen, John W.M. Martens, Maurice P.H.M. Jansen, Job van Riet, Martijn P. Lolkema
Publikováno v:
European Journal of Cancer, 177, 33-44. Elsevier Ltd.
Background: Metastatic castration-resistant prostate cancer (mCRPC) patients with positive AR-V7 expression in their circulating tumour cells (CTCs) rarely derive benefit from abiraterone and enzalutamide. Design: We performed a prospective, multicen
Autor:
Agnieszka Wozniak, Herman Burger, Axelle Nzokirantevye, Erik A.C. Wiemer, Marcel Smid, Raf Sciot, Patrick Schöffski, Stefan Sleijfer, Giuseppe Floris
Publikováno v:
European Journal of Cancer, 75, 33-40. Elsevier Ltd.
Background Recent phase II and III clinical trials demonstrated anti-tumour activity of eribulin, a tubulin-interacting cytotoxic agent, in patients with metastatic soft tissue sarcoma (STS). In this exploratory study, we aimed to identify putative m
Autor:
Patrick Schöffski, Robert G. Maki, Thomas Brodowicz, Jean-Yves Blay, Stefan Sleijfer, George D. Demetri, Akira Kawai
Publikováno v:
European Journal of Cancer, 50(4), 679-689. Elsevier Ltd.
Background Soft tissue sarcomas (STS) are a heterogeneous group of cancers comprising over 50 histological subtypes. Current treatment strategies for sarcomas are increasingly adapted to histological and molecular subtype, and several patient- and tu
Autor:
Jaqueline Kloth, Ron H.J. Mathijssen, Stefan Sleijfer, Alessandro Ruggiero, Jaap Verweij, Gaia Schiavon, Patrick Schöffski, Gabriel P. Krestin, D.J. Bekers, Peter A. Barry
Publikováno v:
European Journal of Cancer, 50(5), 972-980. Elsevier Ltd.
European Journal of Cancer, March, 5, 50, 972-980
European Journal of Cancer, March, 5, 50, 972-980
Purpose: Tumour response assessment to therapy is crucial in oncology. We analysed the morphology of liver metastases (LM) in gastrointestinal stromal tumour (GIST) patients to determine whether uni-dimensional measurement of lesions by Response Eval
Autor:
Inge R. H. M. Konings, Lidemarie J. van der Wijk, Stefan Sleijfer, Ferry A.L.M. Eskens, Felix E. de Jongh, A. van der Gaast
Publikováno v:
European Journal of Cancer, 46(18), 3200-3204. Pergamon
European Journal of Cancer, 46(18), 3200-3204. Elsevier Ltd.
Konings, I R H M, van der Gaast, A, van der Wijk, L J, de Jongh, F E, Eskens, F A & Sleijfer, S 2010, ' The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial ', European Journal of Cancer, vol. 46, no. 18, pp. 3200-3204 . https://doi.org/10.1016/j.ejca.2010.07.036
European Journal of Cancer, 46(18), 3200-3204. Elsevier Ltd.
Konings, I R H M, van der Gaast, A, van der Wijk, L J, de Jongh, F E, Eskens, F A & Sleijfer, S 2010, ' The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial ', European Journal of Cancer, vol. 46, no. 18, pp. 3200-3204 . https://doi.org/10.1016/j.ejca.2010.07.036
Purpose: Statins have for long been considered to play a potential role in anticancer treatment based upon their ability to inhibit the mevalonate synthesis pathway. This randomised phase II trial compared the efficacy and safety of pravastatin added
Autor:
Stefan, Sleijfer, Monia, Ouali, Martine, van Glabbeke, Anders, Krarup-Hansen, Sjoerd, Rodenhuis, Axel, Le Cesne, Pancras C W, Hogendoorn, Jaap, Verweij, Jean-Yves, Blay
Publikováno v:
European journal of cancer (Oxford, England : 1990). 46(1)
Adult patients with advanced soft tissue sarcomas (STS) are generally treated similarly, regardless of great differences between STS subtypes, disease presentation and patients' characteristics. As ifosfamide is frequently applied in first line syste
Autor:
Jaco Kraan, Jan-Willem Gratama, John A. Foekens, Stefan Sleijfer, Anieta M. Sieuwerts, John W.M. Martens
Publikováno v:
European Journal of Cancer, 43(18), 2645-2650. Elsevier Ltd.
Circulating tumour cells (CTCs) have been considered for a long time in reflecting the aggressiveness of tumours. As a result, many attempts have been made to develop assays that reliably detect and enumerate CTCs, but only recently have such assays
Publikováno v:
European Journal of Cancer, 32A(3), 550-552. ELSEVIER SCI LTD
We examined whether cisplatin-induced nephrotoxicity augmented bleomycin-induced pulmonary toxicity in patients with testicular cancer treated with etoposide and cisplatin with (BEP) or without bleomycin (EP). Before and at 3-week intervals during ch